Before MDF2 can be applied in clinical prediction, two fundamental requirements must be met: (1) establishing reference ranges to define low-risk and high-risk thresholds for the MDF2 score, and (2) developing a standardized analytical pipeline for processing RNA-seq or proteomics data from tumour samples. This evidence concerns the gene ITGB1 and neoplasm.